241 related articles for article (PubMed ID: 19422277)
1. Absenteeism and health-benefit costs among employees with MS.
Brook RA; Rajagopalan K; Kleinman NL; Melkonian AK
Curr Med Res Opin; 2009 Jun; 25(6):1469-76. PubMed ID: 19422277
[TBL] [Abstract][Full Text] [Related]
2. Medication adherence with disease modifying treatments for multiple sclerosis among US employees.
Kleinman NL; Beren IA; Rajagopalan K; Brook RA
J Med Econ; 2010; 13(4):633-40. PubMed ID: 20958113
[TBL] [Abstract][Full Text] [Related]
3. Comparing costs and absences for multiple sclerosis among US employees: pre- and post-treatment initiation.
Rajagopalan K; Brook RA; Beren IA; Kleinman NL
Curr Med Res Opin; 2011 Jan; 27(1):179-88. PubMed ID: 21138336
[TBL] [Abstract][Full Text] [Related]
4. An employer perspective on annual employee and dependent costs for pediatric asthma.
Kleinman NL; Brook RA; Ramachandran S
Ann Allergy Asthma Immunol; 2009 Aug; 103(2):114-20. PubMed ID: 19739423
[TBL] [Abstract][Full Text] [Related]
5. The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database.
Joish VN; Donaldson G; Stockdale W; Oderda GM; Crawley J; Sasane R; Joshua-Gotlib S; Brixner DI
Curr Med Res Opin; 2005 Apr; 21(4):535-44. PubMed ID: 15899102
[TBL] [Abstract][Full Text] [Related]
6. The economic impact of bipolar disorder in an employed population from an employer perspective.
Gardner HH; Kleinman NL; Brook RA; Rajagopalan K; Brizee TJ; Smeeding JE
J Clin Psychiatry; 2006 Aug; 67(8):1209-18. PubMed ID: 16965198
[TBL] [Abstract][Full Text] [Related]
7. Functional dyspepsia impacts absenteeism and direct and indirect costs.
Brook RA; Kleinman NL; Choung RS; Melkonian AK; Smeeding JE; Talley NJ
Clin Gastroenterol Hepatol; 2010 Jun; 8(6):498-503. PubMed ID: 20304102
[TBL] [Abstract][Full Text] [Related]
8. Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States.
Ivanova JI; Birnbaum HG; Kidolezi Y; Qiu Y; Mallett D; Caleo S
Epilepsia; 2010 May; 51(5):838-44. PubMed ID: 20002150
[TBL] [Abstract][Full Text] [Related]
9. Effect of antihypertensive medication adherence among employees with hypertension.
Lynch WD; Markosyan K; Melkonian AK; Pesa J; Kleinman NL
Am J Manag Care; 2009 Dec; 15(12):871-80. PubMed ID: 20001168
[TBL] [Abstract][Full Text] [Related]
10. Cost of gastro-oesophageal reflux disease to the employer: a perspective from the United States.
Brook RA; Wahlqvist P; Kleinman NL; Wallander MA; Campbell SM; Smeeding JE
Aliment Pharmacol Ther; 2007 Sep; 26(6):889-98. PubMed ID: 17767473
[TBL] [Abstract][Full Text] [Related]
11. Health benefit costs and absenteeism due to insomnia from the employer's perspective: a retrospective, case-control, database study.
Kleinman NL; Brook RA; Doan JF; Melkonian AK; Baran RW
J Clin Psychiatry; 2009 Aug; 70(8):1098-104. PubMed ID: 19758521
[TBL] [Abstract][Full Text] [Related]
12. The economic burden of gout on an employed population.
Brook RA; Kleinman NL; Patel PA; Melkonian AK; Brizee TJ; Smeeding JE; Joseph-Ridge N
Curr Med Res Opin; 2006 Jul; 22(7):1381-9. PubMed ID: 16834837
[TBL] [Abstract][Full Text] [Related]
13. Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis.
Castelli-Haley J; Oleen-Burkey MA; Lage MJ; Johnson KP
Adv Ther; 2009 May; 26(5):552-62. PubMed ID: 19444392
[TBL] [Abstract][Full Text] [Related]
14. United States comparative costs and absenteeism of diabetic ophthalmic conditions.
Brook RA; Kleinman NL; Patel S; Smeeding JE; Beren IA; Turpcu A
Postgrad Med; 2015 Jun; 127(5):455-62. PubMed ID: 25549691
[TBL] [Abstract][Full Text] [Related]
15. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs.
Su J; Brook RA; Kleinman NL; Corey-Lisle P
Hepatology; 2010 Aug; 52(2):436-42. PubMed ID: 20683943
[TBL] [Abstract][Full Text] [Related]
16. Costs and absence of HCV-infected employees by disease stage.
Baran RW; Samp JC; Walker DR; Smeeding JE; Young JW; Kleinman NL; Brook RA
J Med Econ; 2015; 18(9):691-703. PubMed ID: 26047262
[TBL] [Abstract][Full Text] [Related]
17. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.
Ivanova JI; Birnbaum HG; Samuels S; Davis M; Phillips AL; Meletiche D
Pharmacoeconomics; 2009; 27(8):681-91. PubMed ID: 19712010
[TBL] [Abstract][Full Text] [Related]
18. The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis.
Hersh CM; Brook RA; Beren IA; Rohrbacker NJ; Lebson L; Henke C; Phillips AL
J Med Econ; 2021; 24(1):479-486. PubMed ID: 33739915
[TBL] [Abstract][Full Text] [Related]
19. Cost of multiple sclerosis in the Czech Republic: the COMS study.
Blahova Dusankova J; Kalincik T; Dolezal T; Kobelt G; Havrdova E
Mult Scler; 2012 May; 18(5):662-8. PubMed ID: 21965424
[TBL] [Abstract][Full Text] [Related]
20. Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
